Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | SELP | P16109 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 7/20 | 0.34 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.34 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TACR2 | P21452 | 1/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24086080 | 0.95 | L3MBTL1 (0.49) | L3MBTL1KMT2AMEN1SELPBCHE | |
| SCHEMBL24086064 | 0.95 | L3MBTL1 (0.49) | L3MBTL1KMT2AMEN1SELPBCHE | |
| SCHEMBL7154481 | 0.91 | L3MBTL1 (0.45) | L3MBTL1KMT2AMEN1BCHELGALS9 | |
| SCHEMBL7154294 | 0.89 | L3MBTL1 (0.51) | L3MBTL1KMT2AMEN1SELPALDH1A1 | |
| SCHEMBL25031785 | 0.89 | L3MBTL1 (0.51) | L3MBTL1KMT2AMEN1SELPALDH1A1 | |
| SCHEMBL16731453 | 0.89 | L3MBTL1 (0.40) | L3MBTL1KMT2AMEN1SELPBCHE | |
| SCHEMBL7145164 | 0.88 | L3MBTL1 (0.50) | L3MBTL1KMT2AMEN1SELPBCHE | |
| SCHEMBL7151724 | 0.88 | L3MBTL1 (0.41) | L3MBTL1KMT2AMEN1SELPBCHE | |
| SCHEMBL26492359 | 0.87 | L3MBTL1 (0.50) | L3MBTL1KMT2AMEN1SELPBCHE | |
| SCHEMBL7151504 | 0.86 | L3MBTL1 (0.40) | L3MBTL1KMT2AMEN1BCHELGALS9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344513-A9 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF FONDAPARINUX | ACADEMIA SINICA (TW) | 2015-12-03 | — | — | US | disclosed |
| US-20150126721-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF FONDAPARINUX | ACADEMIA SINICA (TW) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344513-A9 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF FONDAPARINUX | F2, TBXA2R, PROC | L3MBTL1 4460/4885KMT2A 2445/4885MEN1 1419/4885 |
| US-20150126721-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF FONDAPARINUX | F2, TBXA2R, PROC | L3MBTL1 4460/4885KMT2A 2445/4885MEN1 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.